23andMe to delist from Nasdaq, deregister with SEC
Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million.
You are not logged in so some information on this page has been withheld. To see more, please log in.
since
auto-detected in 92 stories
27 days ago
35 days ago
61 days ago
found
62 days ago
found
a story from CNBC ⚠️ › World News
page 1 of 1